Enhanced antibody responses in infants given different sequences of heterogeneous Haemophilus influenzae type b conjugate vaccines

• Published in: The Journal of pediatrics Vol. 126; no. 2; pp. 206 - 211
• Main Authors: Greenberg, David P., Lieberman, Jay M., Marcy, S.Michael, Wong, Victor K., Partridge, Susan, Chang, Swei-Ju, Chiu, Chung-Yin, Ward, Joel I.
• Format: Journal Article
• Language: English
• Published: New York, NY Mosby, Inc 01.02.1995; Elsevier
• Subjects: Aging - immunology; Analysis of Variance; Antibodies, Bacterial - blood; Biological and medical sciences; Epidemiology. Vaccinations; Female; General aspects; Haemophilus influenzae - immunology; Haemophilus Vaccines - administration & dosage; Haemophilus Vaccines - adverse effects; Haemophilus Vaccines - immunology; Humans; Immunization Schedule; Infant; Infectious diseases; Injections, Intramuscular; Male; Medical sciences; Safety; Vaccines, Conjugate - administration & dosage; Vaccines, Conjugate - adverse effects; Vaccines, Conjugate - immunology; Hib; PRP-D; PRP-T; HbOC; CRM; PRP; PRP-OMP; Human; Pasteurellaceae; Prevention; Immunoprotection; Vaccination; Bacteria; Infant; Mixed vaccine; Haemophilus influenzae
• ISSN: 0022-3476; 1097-6833
• DOI: 10.1016/S0022-3476(95)70546-5

To evaluate the safety and immunogenicity of differing sequences of heterogeneous Haemophilus influenzae type b (Hib) conjugate vaccines, we randomly assigned 300 infants to one of six vaccination schedules. At 2, 4, and 6 months of age, subjects were given single or heterogeneous vaccines: Hib polysaccharide (PRP) conjugated to mutant diphtheria toxin (HbOC), PRP conjugated to outer-membrane protein of Neisseria meningitidis (PRP-OMP), or PRP conjugated to tetanus toxoid (PRP-T). No serious reactions were attributable to immunization with heterogeneous vaccines, and there were few significant differences in the rates of minor adverse reactions among groups. PRP-OMP was the only vaccine that induced an antibody response after the first dose, but significant booster responses were not seen after the second and third doses. Subjects given PRP-T vaccine responded well after two doses, but three doses of HbOC vaccine were needed for an equivalent antibody response. All the Hib vaccine schedules evaluated were immunogenic, and schedules initiated by PRP-OMP vaccine at 2 months of age, followed by two doses of either HbOC or PRP-T vaccine at 4 and 6 months of age, induced the highest antibody levels after each dose. Such schedules may be the best for protecting infants and children who are at greatest risk of having invasive Hib disease, such as American Indian children. (J P EDIATR 1995;126:206-11)